MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors

Abstract only 3004 Background: HER2 ( ERBB2) amplification and/or overexpression is observed in 2–3% of solid tumors, and is often associated with more aggressive disease. Thus far, HER2-targeted therapies are FDA-approved only for breast, gastric, and gastroesophageal cancers. MyPathway (NCT0209114...

Full description

Bibliographic Details

Published in:	Journal of clinical oncology Vol. 39; no. 15_suppl; p. 3004
Main Authors:	Meric-Bernstam, Funda, Hainsworth, John, Bose, Ron, Burris III, Howard A., Friedman, Claire Frances, Kurzrock, Razelle, Swanton, Charles, Wang, Yong, Levy, Jonathan, Schulze, Katja, Price, Richard, Patel, Arisha, Sweeney, Christopher
Format:	Journal Article
Language:	English
Published:	20-05-2021
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!